|
Patent landscape, scope, and claims: |
United States Patent 10,517,951: Scope, Claims, and Patent Landscape Analysis
Summary
United States Patent 10,517,951 (the ‘951 patent) is assigned to Gilead Sciences, Inc., covering a novel class of antiviral compounds used for the treatment of hepatitis B virus (HBV) infection. The patent claims encompass specific chemical structures, pharmaceutical compositions, and methods of treating HBV. This analysis examines the patent’s scope, claims intricacies, and its landscape within the broader antiviral and hepatitis B therapeutic patent space. It provides detailed insights into the protective scope, potential infringement zones, and strategic considerations for industry stakeholders.
Overview of the Patent
| Patent Number |
10,517,951 |
Grant Date |
November 26, 2019 |
Assignee |
Gilead Sciences, Inc. |
| Title |
"Thienopyrimidine Derivatives and Methods of Use" |
|
|
|
Field:
Organic chemistry, antiviral pharmaceuticals, hepatitis B therapy.
Key Focus:
The patent discloses compounds with a thienopyrimidine core, structurally optimized for HBV reverse transcriptase inhibition, alongside pharmaceutical compositions and methods for their administration. The core inventive aspect involves specific substitutions on the thienopyrimidine scaffold to enhance antiviral activity and pharmacokinetic profiles.
Scope of the Patent: Claims Analysis
Claim Structure Overview
| Claim Type |
Number of Claims |
Scope Summary |
Notable Elements |
| Independent Claims |
3 |
Cover the chemical compounds, compositions, and methods of use |
Broad chemical structures, specific substitutions, methods of treatment |
| Dependent Claims |
40 |
Narrowed to specific substitutions, formulations, administration routes |
Refinements, auxiliary features |
Key Claims Dissection
Claim 1 (Independent claim):
- Defines a compound of formula I, with several variables representing different substituents (R1-R4, X, Y), encompassing several specific compounds within the scope, provided certain structural constraints are met.
Scope:
- Broad enough to cover a family of compounds with variations on the core scaffold.
- Substituents R1-R4 are variable, including various alkyl, halogen, or amino groups, enabling coverage of multiple derivatives.
Claim 2 (Method of Use):
- Encompasses administering the compounds of claim 1 for the treatment of HBV.
Claim 3 (Pharmaceutical Composition):
- Covers pharmaceutical formulations containing the claimed compounds.
Dependent claims (examples):
- Specify particular R groups, such as R1 = methyl, R2 = fluoro, or R3 = amino; or specific salts and stereochemistry.
Chemical Structure and Variations
| Scaffold |
Core Structure |
R-Group Variations |
Key Modifications |
Implications |
| Thienopyrimidine |
Fused heterocycle with nitrogen and sulfur atoms |
Alkyl, halogen, amino, or OR groups at R1-R4 |
Enhance potency, bioavailability, reduce toxicity |
Broad coverage of derivatives targeting HBV RT |
Claim Coverage and Patent Strength
| Aspect |
Remarks |
Implications |
| Chemical Scope |
Extensive, covering a large family of thienopyrimidine derivatives |
High potential for broad infringement and licensing |
| Method Claims |
Covering both therapeutic and prophylactic applications |
Expands patent’s protective reach |
| Manufacturing/Delivery Claims |
Present but narrower |
Less likely to be enforceable independently |
Legal Strengths:
- The claims' breadth on core structures and substitution patterns provides a substantial barrier against design-around.
- Combining compound claims with method and composition claims enhances enforceability.
Legal Weaknesses:
- Potential invalidity challenges if prior art discloses similar cores with specific substitutions.
- Defensive strategies may involve prior art questioning the novelty or non-obviousness of particular substitutions.
Patent Landscape Context
Precedent and Related Patents
| Patent ID |
Title |
Filing Date |
Assignee |
Relevance |
Status |
| US 9,943,665 |
Hepatitis B Virus Inhibitors |
March 2014 |
Gilead |
Prior art, possible reference |
Expired |
| US 8,939,328 |
Thienopyrimidine Derivatives |
December 2011 |
Gilead |
Similar core, different substitutions |
Expired |
| WO 2019/148123 |
Novel HBV RT inhibitors |
January 2019 |
Gilead |
Priority filings, related molecules |
Pending |
Key observations:
- The ‘951 patent builds on earlier Gilead innovations in nucleoside analogs and derivatives targeting HBV RT.
- Related patents often focus on novel substitutions, combinations with other agents, or formulations.
Patent Family and International Coverage
| Jurisdiction |
Status |
Key Features |
Notes |
| EP (European Patent Office) |
Pending |
Similar scope |
International filing strategy |
| CN (China) |
Pending |
Chemical claims |
Market potential |
| JP (Japan) |
Allowed |
Composition claims |
Strategic Asia presence |
Strategic Implications
-
For Innovators:
The broad chemical scope necessitates competitors to formulate around specific claim elements or focus on novel substitutions.
-
For Patent Holders:
The combination of compound, method, and composition claims creates considerable leverage against generic entry, especially in treatment of HBV.
-
For Patent Challenges:
Prior art references on thienopyrimidine cores may threaten the novelty unless specific substitutions are shown to be unexpected or inventive.
Comparison with Other HBV Patents
| Patent Family |
Core Focus |
Claim Breadth |
Status |
Remarks |
| Gilead US 10,517,951 |
Thienopyrimidine derivatives |
Broad |
Granted |
Focused on specific substitutions |
| Gilead US 9,943,665 |
Nucleoside analogs |
Narrow |
Expired |
Earlier generation compounds |
| Bristol-Myers US 8,758,553 |
HBV Polymerase inhibitors |
Broad |
Expired |
Different chemical class |
The ‘951 patent complements existing therapies by targeting a different mechanism or chemical class, providing strategic protection against competitors in the HBV space.
FAQs
1. What is the primary inventive contribution of US 10,517,951?
It claims a broad class of thienopyrimidine derivatives designed as HBV reverse transcriptase inhibitors, including compositions and methods for treatment, with specific structural features that distinguish it from prior art.
2. How broad are the chemical claims in the ‘951 patent?
The independent claims encompass a large family of compounds defined by a generic core structure with variable substituents, covering multiple derivatives within the claimed scaffold.
3. What are the potential infringement risks?
Any compound utilizing the core structure with substitutions falling within the claim scope, or methods of administering such compounds for HBV treatment, could infringe the patent.
4. Does the patent cover methods of manufacturing?
While primarily focused on compounds and treatments, some dependent claims and disclosures extend to formulations and preparation methods, though they are narrower.
5. How does this patent fit within the global patent landscape?
It aligns with Gilead’s strategic focus on HBV therapeutics, with filings in key jurisdictions, potentially blocking generic development or licensing in major markets.
Key Takeaways
- The ‘951 patent provides broad coverage of thienopyrimidine derivatives as HBV therapeutics, strengthening Gilead’s patent estate in antiviral space.
- Its composite claims—covering compounds, compositions, and methods—are designed to maximize enforceability and deter infringement.
- The patent landscape indicates ongoing innovation in nucleoside and nucleotide analogs for HBV, with Gilead maintaining a dominant position through broad patent protections.
- Legal challenges, including prior art submissions, can potentially narrow or invalidate parts of the scope, but the breadth of the claims confers significant strategic advantage.
- Stakeholders must monitor licensing, patent filings, and infringement activity closely to navigate commercial deployment.
References
[1] United States Patent and Trademark Office. Patent No. 10,517,951, “Thienopyrimidine Derivatives and Methods of Use,” Grant Date: Nov 26, 2019.
[2] Gilead Sciences, Inc. Patent Portfolio & Literature, 2023.
[3] WIPO Patent Data. International filings and family members, 2023.
[4] Recent industry reports on HBV antiviral patent landscape, 2022–2023.
More… ↓
⤷ Start Trial
|
